Clinical Trial

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Name: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer — clinical trial record (NCT05483868)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Protocol Amendment History 1 change

critical Enrollment closed, study ongoing 2026-08-07

Trial Details

NCT Number	NCT05483868
Lead Sponsor	Aura Biosciences
Conditions	Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Enrollment	55 participants
Start Date	2022-09-26
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-06